|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
He J, Shin H, Wei X, Kadegowda AK, Chen R
and Xie SK: NPC1L1 knockout protects against colitis-associated
tumorigenesis in mice. BMC Cancer. 15:1892015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
He J, Liang X, Luo F, Chen X, Xu X, Wang F
and Zhang Z: P53 is involved in a three-dimensional
architecture-mediated decrease in chemosensitivity in colon cancer.
J Cancer. 7:900–909. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
He J, Pei L, Jiang H, Yang W, Chen J and
Liang H: Chemoresistance of colorectal cancer to 5-fluorouracil is
associated with silencing of the BNIP3 gene through aberrant
methylation. J Cancer. 8:1187–1196. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
He JM, Wang FC, Qi HB, Li Y and Liang HJ:
Down-regulation of alphav integrin by retroviral delivery of small
interfering RNA reduces multicellular resistance of HT29. Cancer
Lett. 284:182–188. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liang X, Xu X, Wang F, Chen X, Li N, Wang
C and He J: E-cadherin knockdown increases β-catenin reducing
colorectal cancer chemosensitivity only in three-dimensional
cultures. Int J Oncol. 47:1517–1527. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liang X, Xu X, Wang F, Li N and He J:
E-cadherin increasing multidrug resistance protein 1 via
hypoxia-inducible factor-1alpha contributes to multicellular
resistance in colorectal cancer. Tumour Biol. 37:425–435. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Longmate W and DiPersio CM: Beyond
adhesion: Emerging roles for integrins in control of the tumor
microenvironment. F1000Res. 6:16122017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Das V, Kalyan G, Hazra S and Pal M:
Understanding the role of structural integrity and differential
expression of integrin profiling to identify potential therapeutic
targets in breast cancer. J Cell Physiol. 233:168–185. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zeltz C and Gullberg D: The
integrin-collagen connection-a glue for tissue repair? J Cell Sci.
129:653–664. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bierie B, Pierce SE, Kroeger C, Stover DG,
Pattabiraman DR, Thiru P, Donaher Liu J, Reinhardt F, Chaffer CL,
Keckesova Z, et al: Integrin-β4 identifies cancer stem
cell-enriched populations of partially mesenchymal carcinoma cells.
Proc Natl Acad Sci USA. 114:E2337–E2346. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Phung YT, Barbone D, Broaddus VC and Ho M:
Rapid generation of in vitro multicellular spheroids for the study
of monoclonal antibody therapy. J Cancer. 2:507–514. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tai YL, Lai IR, Peng YJ, Ding ST and Shen
TL: Activation of focal adhesion kinase through an interaction with
beta4 integrin contributes to tumorigenicity of colon cancer. FEBS
Lett. 590:1826–1837. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ye X, Zhang C, Chen Y and Zhou T:
Upregulation of acetylcholinesterase mediated by p53 contributes to
cisplatin-induced apoptosis in human breast cancer cell. J Cancer.
6:48–53. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Valentine JM, Kumar S and Moumen A: A
p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage
response initiation. BMC Cancer. 11:792011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
He J, Wang F, Luo F, Chen X, Liang X,
Jiang W, Huang Z, Lei J, Shan F and Xu X: Effects of long term low-
and high-dose sodium arsenite exposure in human transitional cells.
Am J Transl Res. 9:416–428. 2017.PubMed/NCBI
|
|
18
|
Yogev O, Barker K, Sikka A, Almeida GS,
Hallsworth A, Smith LM, Jamin Y, Ruddle R, Koers A, Webber HT, et
al: p53 loss in MYC-driven neuroblastoma leads to metabolic
adaptations supporting radioresistance. Cancer Res. 76:3025–3035.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Verjans ET, Doijen J, Luyten W, Landuyt B
and Schoofs L: Three-dimensional cell culture models for anticancer
drug screening: Worth the effort? J Cell Physiol. 233:2993–3003.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Godar S, Ince TA, Bell GW, Feldser D,
Donaher JL, Bergh J, Liu A, Miu K, Watnick RS, Reinhardt F, et al:
Growth-inhibitory and tumor-suppressive functions of p53 depend on
its repression of CD44 expression. Cell. 134:62–73. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yoshioka T, Otero J, Chen Y, Kim YM,
Koutcher JA, Satagopan J, Reuter V, Carver B, de Stanchina E,
Enomoto K, et al: β4 Integrin signaling induces expansion of
prostate tumor progenitors. J Clin Invest. 123:682–699.
2013.PubMed/NCBI
|
|
22
|
Bon G, Di Carlo SE, Folgiero V, Avetrani
P, Lazzari C, D'Orazi G, Brizzi MF, Sacchi A, Soddu S, Blandino G,
et al: Negative regulation of beta4 integrin transcription by
homeodomain-interacting protein kinase 2 and p53 impairs tumor
progression. Cancer Res. 69:5978–5986. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lakshmanan I, Rachagani S, Hauke R, Krishn
SR, Paknikar S, Seshacharyulu P, Karmakar S, Nimmakayala RK,
Kaushik G, Johansson SL, et al: MUC5AC interactions with integrin
β4 enhances the migration of lung cancer cells through FAK
signaling. Oncogene. 35:4112–4121. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chao C, Lotz MM, Clarke AC and Mercurio
AM: A function for the integrin alpha6beta4 in the invasive
properties of colorectal carcinoma cells. Cancer Res. 56:4811–4819.
1996.PubMed/NCBI
|
|
25
|
Alon R and Dustin ML: Force as a
facilitator of integrin conformational changes during leukocyte
arrest on blood vessels and antigen-presenting cells. Immunity.
26:17–27. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sarasqueta AF, Forte G, Corver WE, de
Miranda NF, Ruano D, van Eijk R, Oosting J, Tollenaar RA, van Wezel
T and Morreau H: Integral analysis of p53 and its value as
prognostic factor in sporadic colon cancer. BMC Cancer. 13:2772013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li H, Rokavec M, Jiang L, Horst D and
Hermeking H: Antagonistic effects of p53 and HIF1A on microRNA-34a
regulation of PPP1R11 and STAT3 and hypoxia-induced epithelial to
mesenchymal transition in colorectal cancer cells.
Gastroenterology. 153:505–520. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tran TQ, Lowman XH, Reid MA,
Mendez-Dorantes C, Pan M, Yang Y and Kong M: Tumor-associated
mutant p53 promotes cancer cell survival upon glutamine deprivation
through p21 induction. Oncogene. 36:1991–2001. 2017. View Article : Google Scholar : PubMed/NCBI
|
